Commissioners handed return-on-investment tool to help build business case for CVD prevention

Public Health England’s new online tool could help commissioners decide how best to prevent cardiovascular disease among their local population.

7 November 2018, by Siobhan Chan

Person using computer

A new return-on-investment tool from public health chiefs could help commissioners in England decide which interventions to prevent cardiovascular disease (CVD) are most likely to work and reduce NHS costs.

Public Health England (PHE)’s CVD Prevention Return on Investment Tool, developed by the University of Sheffield, shows how different interventions are likely to reduce the number of CVD events and premature deaths and free up NHS resources.

It also shows the effectiveness of different approaches to detecting and managing people with high-risk conditions such as hypertension or atrial fibrillation (AF).

PHE’s tool presents statistics at national, local authority, clinical commissioning group, or sustainability and transformation partnership level.

Professor Jamie Waterall, PHE National Lead for Cardiovascular Disease Prevention, said: “[The tool] will help commissioners plan effective CVD prevention strategies and make the most of their budgets to help more people live healthier, longer lives.”

Screenshot of return on investment tool

Screenshot of the tool in use

Evidence-based health

Jenny Hargrave, BHF Director of Innovation in Health and Wellbeing, said: “Too often, decision makers are unable to implement evidence-based health service improvements for patients with heart and circulatory disease, as they cannot provide a clear financial business case for the intervention.

“We therefore welcome the development of this tool and look forward to seeing its impact in influencing commissioning decisions that benefit patient outcomes.”

A report accompanying the tool gives examples of the types of analysis that can be carried out. It says statins are the most cost-saving intervention in the short term and anti-hypertensives in the long term.

Identifying and managing people with a QRISK score of 10%, and optimising statin use, have the best short-term health outcomes, it explains. Better detection and management of diabetes can deliver long-term health benefits.

Dr Matt Kearney, GP and NHS England National Clinical Director for CVD Prevention, said: “This return-on-investment tool will show health professionals in each part of the country how heart problems and strokes could be prevented, and how much health service resource could be freed up for reinvestment if we increase detection and treatment of high-risk conditions like AF, high blood pressure and high cholesterol.”

Around 5.9 million people live with CVD in England, and this costs the NHS £7.4 billion each year, according to PHE.

Access the tool now


BHF resources for commissioners

The BHF’s service innovation programmes identify areas where our investment has led to cost savings and improved patient health.

Want to implement a CVD programme in your area? Read our guide to building a business case.